Summary of the Conference Call on Rebio Biotech Company Overview - Rebio Biotech (06938) is a global leader in small nucleic acid drug development, with a proven and mature drug development platform [2][3]. Key Points - **Development Platform**: The company has developed the GalNAc liver-targeting RiboGalSTAR platform, which has evolved from liver-targeting to extrahepatic targeting. Continuous chemical modifications enhance target specificity and sequence compatibility while reducing off-target effects, improving efficacy and safety [2][3]. - **Intellectual Property**: As of the end of 2025, Rebio holds 473 patents and patent applications across major jurisdictions, establishing a comprehensive intellectual property portfolio [4]. - **Full Lifecycle Coverage**: The R&D platform integrates the entire technical chain, ensuring efficiency from CMC production and early research to commercialization [4]. - **Clinical Assets**: Rebio is one of the Chinese small nucleic acid companies with the most clinical assets. By the end of 2025, the company has seven siRNA pipelines in clinical stages, with four in Phase II. Key assets include: - RBD4059 (FXI): The world's first and fastest clinical progress siRNA drug for thrombotic diseases, expected to start Phase IIb clinical trials in 2026 [5]. - RBD5044 (ApoC3): The second siRNA for ApoC3 to enter clinical stages, following Arrowhead [5]. - RBD1016 (HBV): Currently validating its drugability for HBV [5]. Market Position and Outlook - **Market Concerns**: There are market concerns regarding the drugability of FXI inhibitors. However, Rebio believes that FXI inhibitors have validated drugability in conditions such as stroke and post-knee replacement surgery. FXI siRNA is expected to tackle atrial fibrillation indications due to its higher target inhibition rate [6]. - **Catalysts for Growth**: Potential catalysts include industry data mapping for FXI inhibitors and ApoC3 siRNA, as well as the initiation of multiple Phase II clinical trials and data readouts for Rebio's small nucleic acid drugs [6]. - **Investment Rating**: The company is rated as outperforming the industry, with a target price of HKD 100.00, indicating a potential upside of 44.9% from the current stock price [6].